Quick Answer
Anebulo Pharmaceuticals, Inc. reported Stockholders Equity of $11.66 million for fiscal year 2025.
Anebulo Pharmaceuticals, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $11.66M | +205.8% |
| 2024 | $3.81M | -64.0% |
| 2023 | $10.60M | -29.6% |
| 2022 | $15.07M | -29.6% |
| 2021 | $21.41M | +12611.5% |
| 2020 | -$171.1K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $7.94M | -47.0% | -18.5% |
| September 30, 2025 | $9.74M | +412.8% | -16.5% |
| June 30, 2025 | $11.66M | +205.8% | -13.4% |
| March 31, 2025 | $13.46M | +170.0% | -10.0% |
| December 31, 2024 | $14.96M | +130.6% | +688.0% |
| September 30, 2024 | $1.90M | -77.2% | -50.2% |
| June 30, 2024 | $3.81M | -64.0% | -23.5% |
| March 31, 2024 | $4.99M | -61.5% | -23.2% |
- Anebulo Pharmaceuticals, Inc. showed an increase of +205.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2020–2025 period, Anebulo Pharmaceuticals, Inc.’s stockholders equity has grown by 6912.0% (from -$171.1 thousand to $11.66 million).
- The most recent figure is from Anebulo Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: